Special Issue

Cancer Immunotherapy: Drugs, Predictive Markers, Successes and Failures

Message from the Guest Editor

The immunotherapy of cancer has advanced tremendously in the last decade, transforming the standard of care for many cancer types. This Issue aims to provide reviews of approved and investigational immune drugs in different categories: immune checkpoint drugs, adoptive cell transfer, immune cytokines, drugs activating the innate immune system and combinations thereof, or combinations with chemotherapy or targeted drugs. Some drugs in each category already have a proven track record in cancer treatment, while others are lagging behind for various reasons. The problems slowing down the progress could be ascribed to the lack of predictive markers of response to immune interventions; the relative prevalence of immune-cold cancers in general; and lack of a strong scientific rationale for the design of trials with drug combinations.

Guest Editor

Dr. Emma Shtivelman

Chief Scientist at Cancer Commons, Los Altos, CA, USA

Deadline for manuscript submissions

closed (15 September 2020)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/43403

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

